Accessibility Menu
Arvinas logo

Arvinas(NASDAQ) ARVN

Market Cap$518.11MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2018)-50%
5 Year-92%
1 Year+8%
1 Month-2%
$8.02
-3.37%
-0.28Today
After hours$8.03+$0.01 (+0.13%)
Arvinas last closing stock price
MetricPriceDate
Last closeUSD 8.032026-07-31
Arvinas stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 8.032026-07-24
1 month-2.07%USD 8.202026-07-01
3 month-23.6%USD 10.512026-05-01
Year to date-32.29%USD 11.862025-12-31
1 year+7.93%USD 7.442025-07-31
3 year-67.7%USD 24.862023-08-01
5 year-92.06%USD 101.102021-07-30
Since inception-49.97%USD 16.052018-09-27

Arvinas Financials at a Glance

Market Cap

$518.11MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$89.40M

Net Income (TTM)

-$221.30M

EPS (TTM)

-$3.26

P/E Ratio

-2.47

Dividend

$0.00

Beta (Volatility)

1.42 (Average)

Price

$8.02

Volume

687,895.238

Open

$8.24

Previous Close

$8.03

Daily Range

$7.90 - $8.24

52-Week Range

$6.06 - $14.51

Estimated Earnings Date

Aug 4, 2026

ARVN News

rising bar chart with arrow

Why Arvinas Jumped 10% Today

James BrumleyJul 22, 2021
GettyImages-585166608

Here's Why Arvinas Shares Are Tumbling 13.7% Today

Todd CampbellMay 14, 2020
GettyImages-1129515532

What Company Will Eli Lilly Buy Next?

David HaenJan 23, 2020
cash-drugs-opportunity-hiding-in-plain-sight

2 Biotech Stocks That Soared Last Week

Cory RenauerOct 28, 2019

ARVN: Motley Fool Moneyball Superscore

67

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Arvinas

Arvinas makes medicines that destroy harmful proteins inside the body. These treatments help people fighting cancer and brain diseases. The technology treats conditions that traditional drugs often cannot reach.

Destroying Disease Proteins

  • Breast Cancer Therapy: Oral treatment targeting specific receptors in metastatic breast cancer patients; currently under regulatory review for potential approval.
  • Neurology Program: Experimental drugs designed to cross the blood-brain barrier to treat patients with Parkinson’s disease.
  • Tumor Degraders: Clinical-stage candidates targeting specific protein mutations in lung, pancreatic, and colorectal cancers.
  • Neuromuscular Research: Targeted therapy for men living with a rare genetic muscle-wasting disease called SBMA.

Major Partnerships and Sales Plans

  • Partnered with Pfizer in July 2021 to co-develop and sell the company’s lead breast cancer treatment.
  • Licensed a prostate cancer drug program to Novartis in the second quarter of 2024 for global development.
  • Agreed with Pfizer in the third quarter of 2025 to select a third party for future product sales.
  • Maintains research collaborations with Genentech, Roche, and Bayer to find new medicine targets.

What Makes Arvinas Different?

Arvinas uses a unique technology called PROTAC to reach and remove proteins that were previously considered undruggable by traditional methods. The company has successfully moved seven different programs from its research platform into human clinical trials.

By the Numbers

  • Revenue was $9.5 million in Q4 2025, down 84% from $59.2 million in Q4 2024.
  • Net income was -$67.4 million in Q4 2025, worsening from -$45.1 million in Q4 2024.
  • Free cash flow reached -$30.6 million in Q4 2025, an improvement of 63.7% year-over-year.
  • Operating income was -$71.7 million in Q4 2025, a 23.2% deepening from the previous year.

A Clinical-Stage Evolution

Arvinas has transitioned from a discovery platform to a company with products awaiting regulatory approval. Its recent shift toward finding external commercial partners reflects a strategic focus on research and pipeline development.

AI Generated • May 4, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

246

CEO

Randy Teel, PhD

Website

www.arvinas.com

Headquarters

New Haven, CT 06511, US

ARVN Financials

Key Financial Metrics (TTM)

Gross Margin

97.43%

Operating Margin

-279.31%

Net Income Margin

-247.54%

Return on Equity

-44.39%

Return on Capital

-25.95%

Return on Assets

-34.18%

Earnings Yield

-40.49%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$518.11MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

64.52M

Volume

687.90K

Avg. Volume

820.65K

Financials (TTM)

Gross Profit

$87.10M

Operating Income

-$249.70M

EBITDA

-$216.50M

Operating Cash Flow

-$254.10M

Capital Expenditure

-$2.80M

Free Cash Flow

-$256.90M

Cash & ST Invst.

$614.90M

Total Debt

$8.60M

Arvinas Performance Analysis

Arvinas annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 131,400,000145.1%
20232023-12-31USD 78,500,000-40.3%
20242024-12-31USD 263,400,000235.5%
20252025-12-31USD 262,600,000-0.3%
Arvinas sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-88.1%
Q32025-09-3087.1%
Q42025-12-31-77.3%
Q12026-03-3164.2%
Arvinas annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -5.3139.0%
20232023-12-31USD -6.6224.6%
20242024-12-31USD -2.77-58.2%
20252025-12-31USD -1.14-58.8%
Arvinas sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-173.7%
Q32025-09-3042.9%
Q42025-12-31-116.7%
Q12026-03-3113.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$15.60M

-91.7%

Gross Profit

$14.50M

-92.3%

Gross Margin

92.95%

N/A

Market Cap

$518.11MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.11M

N/A

Employees

246

N/A

Net Income

-$57.60M

-169.5%

EBITDA

-$56.40M

-166.8%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$614.90M

-35.6%

Total Debt

$8.60M

-18.1%

Accounts Receivable

$6.40M

-23.8%

Inventory

$0.00

N/A

Long Term Debt

$6.60M

-23.3%

Short Term Debt

$2.00M

+5.3%

Return on Assets

-34.18%

N/A

Return on Invested Capital

-46.97%

N/A

Free Cash Flow

-$70.50M

+21.1%

Operating Cash Flow

-$69.20M

+22.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
DNAGinkgo Bioworks Holdings, Inc.
$8.09+0.00%
VALNValneva SE
$4.97-2.28%
GERNGeron Corporation
$1.29-3.73%
REPLReplimune Group, Inc.
$11.20+107.02%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$200.75+0.03%
AAPLApple
$308.91-0.07%
AMZNAmazon
$271.58+0.15%
INTCIntel
$90.20-0.01%

Questions About ARVN

What is the current price of Arvinas?

Arvinas is trading at $8.03 per share.

What is the 52-week range for Arvinas?

Over the past 52 weeks, Arvinas has traded between $6.06 and $14.51.

How much debt does Arvinas have?

As of the most recent reporting period, Arvinas reported total debt of $8.60M.

How much cash does Arvinas have on hand?

Arvinas reported $87.30M in cash and cash equivalents in its most recent financial results.

What is Arvinas’s dividend yield?

Arvinas does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services